The SPDR Select Sector Health Care ETF has climbed approximately 18% since June 1, significantly outpacing the broader S&P 500 index, which has remained largely stagnant over the same period. This recent dominance was driven by the sector’s historical insulation from macroeconomic volatility, a trend that appears to be losing momentum as market participants prioritize yield-sensitive alternatives.

Individual performance within the sector faced intense pressure today, underscored by a sharp decline in biotech stocks. Shares of Ultragenyx plummeted by roughly 45% following disappointing developments regarding the company’s gene therapy candidate intended to treat a rare neurodegenerative disease.